Synedgen, Inc.
Synedgen is a company dedicated to developing first-in-class therapeutics that improve patient outcomes by promoting barrier function to repair mucosal injury, particularly in the gastrointestinal (GI) tract. Their lead asset, MIIST305, is an orally delivered therapeutic designed to repair GI mucosal injury, restore GI function, and reduce inflammation and damage. The company's mission is to protect, restore, and repair the body through targeted therapies, scalable GMP production, excellent safety profiles, and a strong IP position.
Industries
Nr. of Employees
small (1-50)
Synedgen, Inc.
Claremont, California, United States, North America
Products
Clinic‑ready orally delivered GI mucosal‑repair therapeutic
An orally administered therapeutic candidate designed to restore gastrointestinal mucosal function and reduce inflammation and tissue damage; presented as a clinic‑ready lead asset.
Glycomics-based discovery platform
Discovery platform leveraging glycomics to identify and develop therapeutic molecules that promote mucosal barrier repair and regeneration.
Clinic‑ready orally delivered GI mucosal‑repair therapeutic
An orally administered therapeutic candidate designed to restore gastrointestinal mucosal function and reduce inflammation and tissue damage; presented as a clinic‑ready lead asset.
Glycomics-based discovery platform
Discovery platform leveraging glycomics to identify and develop therapeutic molecules that promote mucosal barrier repair and regeneration.
Services
Preclinical development and testing
Preclinical efficacy and safety testing of therapeutic candidates in animal models to support progression toward clinic.
GMP manufacturing scale-up
Production and scale-up of therapeutic candidates under GMP to support clinical supply.
Preclinical development and testing
Preclinical efficacy and safety testing of therapeutic candidates in animal models to support progression toward clinic.
GMP manufacturing scale-up
Production and scale-up of therapeutic candidates under GMP to support clinical supply.
Expertise Areas
- Gastrointestinal disease therapeutics
- Mucosal barrier repair and regeneration
- Glycomics-based therapeutic discovery
- Preclinical efficacy testing in rodent models
Key Technologies
- Glycomics / glycan-based therapeutics
- Oral drug formulation
- Murine (rodent) preclinical disease models
- GMP manufacturing processes